Medivation, Inc.

Press Releases

Company News
View Summary Medivation Announces Participation at Upcoming Investor Conference
Dec 17, 2014
PDF 9.3 KB Add to Briefcase
View Summary Data Presented From Phase 2 Study of Enzalutamide in Advanced Androgen-Receptor Positive, Triple-Negative Breast Cancer
Dec 12, 2014
PDF 160.3 KB Add to Briefcase
View Summary Phase 3 PREVAIL Trial Named Clinical Advance of the Year by SCRIP
Dec 10, 2014
PDF 156.0 KB Add to Briefcase
View Summary Joseph Lobacki to Become Medivation's Chief Commercial Officer
Nov 25, 2014
PDF 9.7 KB Add to Briefcase
View Summary Medivation CEO David Hung Named National EY Entrepreneur Of The Year 2014 Overall Award Winner
Nov 17, 2014
PDF 10.6 KB Add to Briefcase
View Summary Medivation Reports Third Quarter Financial Results and Provides Corporate Update
Nov 6, 2014
PDF 167.7 KB Add to Briefcase
View Summary Medivation Announces Participation at Upcoming Investor Conference
Nov 5, 2014
PDF 9.3 KB Add to Briefcase
View Summary Medivation and Astellas Announce Phase 3 Study of Enzalutamide in Men With High-Risk, Hormone-Sensitive, Non-Metastatic Prostate Cancer That Has Recurred Following Definitive Local Therapy
Oct 30, 2014
PDF 158.7 KB Add to Briefcase
View Summary Medivation Announces Participation at Upcoming Investor Conference
Oct 28, 2014
PDF 9.1 KB Add to Briefcase
View Summary Medivation Inc. Licenses Clinical Stage Anti-PD-1 Immune Modulatory Monoclonal Antibody From CureTech Ltd. for Potential Applications in Oncology
Oct 23, 2014
PDF 12.3 KB Add to Briefcase
View Summary Medivation Announces Third Quarter 2014 Financial Results Teleconference on November 6, 2014
Oct 23, 2014
PDF 9.1 KB Add to Briefcase
View Summary U.S. FDA Approves New Indication for the Use of XTANDI(R) (Enzalutamide) Capsules for Patients With Metastatic Castration-Resistant Prostate Cancer
Sep 10, 2014
PDF 159.4 KB Add to Briefcase
View Summary Medivation Announces Participation at Upcoming Investor Conference
Aug 25, 2014
PDF 9.6 KB Add to Briefcase
View Summary Medivation Reports Second Quarter Financial Results and Provides Corporate Update
Aug 7, 2014
PDF 77.3 KB Add to Briefcase
View Summary Medivation Announces Second Quarter 2014 Financial Results Teleconference on August 7, 2014
Jul 24, 2014
PDF 9.0 KB Add to Briefcase
View Summary Medivation Announces Change in Executive Management Team
Jul 10, 2014
PDF 55.7 KB Add to Briefcase
View Summary Medivation Again Voted Among Top Workplaces in the SF Bay Area
Jun 16, 2014
PDF 11.0 KB Add to Briefcase
View Summary Medivation Founder, President and Chief Executive Officer David Hung, M.D. Named an EY Entrepreneur Of The Year(TM) 2014 Award Winner in Northern California
Jun 11, 2014
PDF 11.1 KB Add to Briefcase
View Summary New England Journal of Medicine Publishes Results From Phase 3 PREVAIL Trial of Enzalutamide in Men With Chemotherapy-Naive Metastatic Prostate Cancer Progressing Despite Androgen Deprivation Therapy
Jun 1, 2014
PDF 62.1 KB Add to Briefcase
View Summary Enzalutamide Data, Including Additional Results From the PREVAIL Trial, to Be Presented at Upcoming ASCO Annual Meeting
May 14, 2014
PDF 60.9 KB Add to Briefcase
Showing 1-20 of 315 Page: 1 2 3 4 5 ... 16  Next 20
Add to Briefcase = add release to Briefcase